This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: agents

March 2010 Br J Cardiol 2009;17(Suppl 1):S3-S4

How do antithrombotics work?

Gordon Lowe

Abstract

Mechanisms Figure 1. Platelet-fibrin thrombus in a coronary artery of a patient with acute coronary syndrome The mechanism of action of aspirin differs from that of other antiplatelet agents. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), completely inhibiting COX-1- dependent synthesis of thromboxane A2 (TXA2), a substance which is a potent vasoconstrictor and promoter of platelet aggregation. Whether low-dose aspirin also exerts a significant anti-inflammatory effect is uncertain: a retrospective sub-analysis suggested that it was more effective in primary prevention in individuals who had high levels of C-reacti

| Full text

March 2010 Br J Cardiol 2009;17(Suppl 1):S10-11

Is dual antiplatelet therapy needed for all CVD patients?

Ranil de Silva

Abstract

Dual antiplatelet therapy for all CVD patients? Table 1. Currently used antiplatelet drugs Currently used antiplatelet drugs are summarised in table 1 and pivotal clinical trials of dual antiplatelet therapy in table 2. The Clopidogrel for High Atherothrombotic Risk and Ischaemia Stabilisation, Management and Avoidance (CHARISMA) trial2 is the only prospective randomised clinical trial to evaluate the efficacy and safety of dual antiplatelet therapy in all CVD patients. Initiated after the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial had shown a 9% relative risk reduction with clopidogrel compared w

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now